We rank companies based on fund manager, research analyst and news sentiment
WST stock icon

West Pharmaceutical
WST

$384.08
1.07%
 

About: West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Employees: 10,600

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

31% more call options, than puts

Call options by funds: $47.8M | Put options by funds: $36.5M

7% more first-time investments, than exits

New positions opened: 89 | Existing positions closed: 83

1.0% more ownership

Funds ownership: 91.38% [Q3] → 92.38% (+1.0%) [Q4]

1% more funds holding

Funds holding: 740 [Q3] → 746 (+6) [Q4]

6% less capital invested

Capital invested by funds: $25.4B [Q3] → $24B (-$1.43B) [Q4]

16% less repeat investments, than reductions

Existing positions increased: 250 | Existing positions reduced: 296

56% less funds holding in top 10

Funds holding in top 10: 9 [Q3] → 4 (-5) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$375
2%
downside
Avg. target
$443
15%
upside
High target
$536
40%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
UBS
John Sourbeer
2%downside
$375
Neutral
Maintained
16 Feb 2024
Keybanc
Paul Knight
22%upside
$470
Overweight
Maintained
13 Feb 2024
Jefferies
David Windley
40%upside
$536
Buy
Upgraded
7 Feb 2024
Stephens & Co.
Jacob Johnson
2%upside
$390
Overweight
Maintained
27 Oct 2023

Financial journalist opinion